SUN COMMERCIAL BANK, LTD Sample Clauses

SUN COMMERCIAL BANK, LTD. LOS ANGELES BRANCH, as a Lender By: /s/ Exxxxx Xxxx Name: Exxxxx Xxxx Title: Senior VP & GM By: /s/ Exxx Xxxxxxx Name: Exxx Xxxxxxx Title: Vice President TAIWAN BUSINESS BANK, LOS ANGELES BRANCH, as a Lender By: /s/ Sxxxx Xxxx Name: Sxxxx Xxxx Title: General Manager CXXXX XXX COMMERCIAL BANK, LTD. LOS ANGELES BRANCH, as a Lender By: /s/ Kxxx Xxxx Name: Kxxx Xxxx Title: VP & General Manager FirstMerit Bank, N.A., as a Lender By: /s/ Sxxxxxx Xxxxxx Name: Sxxxxxx Xxxxxx Title: Vice President TriState Capital Bank, as a Lender By: /s/ Exxxx Xxxxx Name: Exxxx Xxxxx Title: Senior Vice President 60000000 BANK OF AMERICA, N.A. WE 350 KNOTTER $ 200,000.00 5/31/2016 USD 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 53,570.45 8/31/2015 EUR 60000000 BANK OF AMERICA, N.A. SUMITOMO MITSUI BANK $ 4,037,950.00 6/30/2015 JPY 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 58,155.80 6/30/2015 CHF 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 58,155.80 6/30/2015 CHF 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 27,768.95 10/31/2015 CHF 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 68,585.05 6/30/2015 CHF 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 47,694.75 6/30/2015 CHF 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 44,515.10 6/30/2015 CHF 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 192,366.90 12/31/2015 NOK 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 58,155.80 6/30/2015 CHF 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 81,561.00 6/30/2015 EUR 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 530,885.28 6/30/2015 EUR 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 52,464.23 6/30/2015 CHF 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 20,985.69 6/30/2015 CHF 60000000 BANK OF AMERICA, N.A. 50 XXXXXXXXX XXXXXXX $ 380,533.50 8/15/2015 USD 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 837,727.24 6/30/2015 EUR 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 389,640.58 6/30/2015 EUR 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 2,288,700.00 4/09/2016 GBP 60000000 BANK OF AMERICA, N.X. XXXXXXX NATIONAL INS $ 115,000.00 8/15/2015 USD 60000000 BANK OF AMERICA, N.A. BANK OF AMERICA, N.A. $ 68,926.72 7/31/2015 EUR 60000000 BANK OF AMERICA, N.A. UP 40/00 XXXXXX XX $ 96,390.00 8/07/2015 USD None. Alexion Pharmaceuticals Australasia Pty Ltd. Alexion Pharma France S.A.S. Alexion Pharma UK Limited Alexion Pharma Belgium SPRL Alexion Pharma Spain S.X. Xxxx...
Sample 1
AutoNDA by SimpleDocs
SUN COMMERCIAL BANK, LTD. 1 The security ratings above are not a recommendation to buy, sell or hold the notes offered hereby. The ratings may be subject to revision or withdrawal at any time by Mxxxx’x Investors Service, Inc., Standard & Poor’s Ratings Service and Fitch Ratings Limited. Each of the security ratings above should be evaluated independently of any other security rating. 2 The TPEx is not responsible for the content of this document and no representation is made by the TPEx as to the accuracy or completeness of this document. The TPEx expressly disclaims any and all liability for any losses arising from, or as a result of the reliance on, all or part of the content of this document. Admission to listing and trading of the Notes on the TPEx shall not be taken as an indication of the merits of the Republic or the Notes. 3 Mxxxxxx Lxxxx International is not licensed in the Republic of China and has therefore not offered or sold, and will not subscribe for, underwrite or sell any of the Notes offered hereby. The following additional information of the Republic of Chile and regarding the securities is available from the SEC’s website and also accompanies this term sheet: · hxxxx://xxx.xxx.xxx/Xxxxxxxx/exxxx/data/19957/000110465920004446/a19-25085_2sba.htm · hxxxx://xxx.xxx.xxx/Xxxxxxxx/exxxx/data/19957/000119312520131194/d925179d18k.htm · hxxxx://xxx.xxx.xxx/Xxxxxxxx/exxxx/data/19957/000119312520132929/d923768d18ka.htm · hxxxx://xxx.xxx.xxx/Xxxxxxxx/exxxx/data/19957/000119312520295145/d20186d18ka.htm · hxxxx://xxx.xxx.xxx/Xxxxxxxx/exxxx/data/19957/000119312520296695/d79542d18ka.htm · hxxxx://xxx.xxx.xxx/Xxxxxxxx/exxxx/data/19957/000110465921004809/a21-2042_118ka.htm · hxxxx://xxx.xxx.xxx/Xxxxxxxx/exxxx/data/0000019957/000110465921042977/tm2110642d2_18ka.htm · hxxxx://xxx.xxx.xxx/Xxxxxxxx/exxxx/data/0000019957/000110465921043532/tm2110642d1_424b3.htm Delivery of the Notes is expected on or about April 15, 2021, which will be the tenth Business Day following the date of pricing of the Notes. Under Rule 15c6–1 of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in two Business Days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the Closing Date may be required, by virtue of the fact that the notes initially will settle in T+10, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers...
Sample 1
SUN COMMERCIAL BANK, LTD 
Sample 1

Related to SUN COMMERCIAL BANK, LTD

  • Name of the Company The name of the Company shall be Envision Pharmaceutical Services, LLC, or such other name as the Member may from time to time hereafter determine, the execution and filing with the State Office of a certificate of amendment to the Articles of Organization by the Member or any person authorized by the Member (or any officer) to be conclusive evidence of any such determination. The business of the Company may be conducted upon compliance with all applicable laws, under any other name designated by the Member; provided that such name contains the words “Limited Liability Company” or the abbreviation “L.L.C.” or the designation “LLC”.

  • Mobile Banking If Mobile Banking is activated for your account(s), you will be required to use secure login information to access the account(s). At the present time, you may use Mobile Banking to:

  • Bank Holding Company Borrower is not a “bank holding company” or a direct or indirect subsidiary of a “bank holding company” as defined in the Bank Holding Company Act of 1956, as amended, and Regulation Y thereunder of the Board of Governors of the Federal Reserve System.

  • Investment Management If and to the extent requested by the Advisor, the Sub-Advisor shall, subject to the supervision of the Advisor, manage all or a portion of the investments of the Portfolio in accordance with the investment objective, policies and limitations provided in the Portfolio's Prospectus or other governing instruments, as amended from time to time, the Investment Company Act of 1940 (the "1940 Act") and rules thereunder, as amended from time to time, and such other limitations as the Trust or Advisor may impose with respect to the Portfolio by notice to the Sub-Advisor. With respect to the portion of the investments of the Portfolio under its management, the Sub-Advisor is authorized to make investment decisions on behalf of the Portfolio with regard to any stock, bond, other security or investment instrument, and to place orders for the purchase and sale of such securities through such broker-dealers as the Sub-Advisor may select. The Sub-Advisor may also be authorized, but only to the extent such duties are delegated in writing by the Advisor, to provide additional investment management services to the Portfolio, including but not limited to services such as managing foreign currency investments, purchasing and selling or writing futures and options contracts, borrowing money or lending securities on behalf of the Portfolio. All investment management and any other activities of the Sub-Advisor shall at all times be subject to the control and direction of the Advisor and the Trust's Board of Trustees.

  • Asset Management Supplier will: i) maintain an asset inventory of all media and equipment where Accenture Data is stored. Access to such media and equipment will be restricted to authorized Personnel; ii) classify Accenture Data so that it is properly identified and access to it is appropriately restricted; iii) maintain an acceptable use policy with restrictions on printing Accenture Data and procedures for appropriately disposing of printed materials that contain Accenture Data when such data is no longer needed under the Agreement; iv) maintain an appropriate approval process whereby Supplier’s approval is required prior to its Personnel storing Accenture Data on portable devices, remotely accessing Accenture Data, or processing such data outside of Supplier facilities. If remote access is approved, Personnel will use multi-factor authentication, which may include the use of smart cards with certificates, One Time Password (OTP) tokens, and biometrics.

  • Managing Director 1. The Managing Director shall be appointed by the Board of Governors from among candidates having the nationality of an ESM Member, relevant international experience and a high level of competence in economic and financial matters. Whilst holding office, the Managing Director may not be a Governor or Director or an alternate of either. 2. The term of office of the Managing Director shall be five years. He or she may be re-appointed once. The Managing Director shall, however, cease to hold office when the Board of Governors so decides. 3. The Managing Director shall chair the meetings of the Board of Directors and shall participate in the meetings of the Board of Governors. 4. The Managing Director shall be chief of the staff of the ESM. He or she shall be responsible for organising, appointing and dismissing staff in accordance with staff rules to be adopted by the Board of Directors. 5. The Managing Director shall be the legal representative of the ESM and shall conduct, under the direction of the Board of Directors, the current business of the ESM.

  • Xxxxxxxxx President Secretary-Treasurer Bricklayers & Allied Craftworkers

  • Financial Services Article 116

  • AGREED AND ACCEPTED The Company has advised the Executive of the Executive’s right to review this Release with the Executive’s own attorney. The Executive has had the opportunity to carefully read this Release and understands all its terms. In agreeing to sign this Release, the Executive has not relied on any oral statements or explanations made by the Company or any other Released Party, including their employees or attorneys. The Executive understands and agrees to be bound by this Release. This Release shall be effective as of the date signed by the Executive (“Effective Date”). Dated: , 20 (Effective Date) Signature Name: In further consideration for the payment of severance payments and benefits provided under the Separation Pay Agreement between (i) Xxxxx X. Xxxxx (the “Executive”) and (ii) Xxxxxx Medical Group, Inc. (the “Company”), the Executive, for himself or herself and the Executive’s heirs, executors, administrators, and assigns, hereby unconditionally releases and forever discharges the Company and each of the Company’s stockholders, predecessors, successors, assigns, agents, directors, officers, employees, representatives, attorneys, divisions, subsidiaries, affiliates, and all persons acting by, through, under, or in concert with any of them (collectively, the “Released Party”) from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, actions, causes of action, suits, rights, demands, costs, losses, debts, and expenses (including attorneys’ fees and costs actually incurred) of any nature whatsoever, known or unknown, suspected or unsuspected arising out of or relating to the Executive’s employment with the Company or termination of such employment, including, but not limited to, claims under the Age Discrimination in Employment Act of 1967 (“ADEA”), as amended from time to time, and other federal, state, or local laws prohibiting discrimination, any claims the Executive may have with regard to the Executive’s hiring, employment, and separation from employment, and any claims growing out of any legal restrictions on the Company’s right to terminate its employees (“Claim(s)”), which the Executive now has, owns or holds, or claims to have owned or held, or which the Executive at any time may have had or claimed to have had against the Company. More specifically, by signing this Release, the Executive agrees to release any actual and potential Claim that the Executive has or may potentially have, either as an individual or standing in the shoes of the government, under any federal, state or local law, administrative regulation or legal principle (except as provided below in this Release) against the Company or any other Released Parties. The following listing of laws and types of Claims is not meant to, and shall not be interpreted to, exclude any particular law or type of Claim, law, regulation or legal principle not listed. The Executive understands that the Executive is releasing all the Executive’s Claims against the Company and all Released Parties including, but not limited to any Claims for expense reimbursement or expenses, relocation assistance Claims for invasion of privacy; breach of written or oral, express or implied, contract; fraud or misrepresentation; Claims for assault, battery, defamation, intentional or negligent infliction of emotional distress, breach of the covenant of good faith and fair dealing, promissory estoppel, negligence, negligent hiring, retention or supervision, retaliation, constructive discharge, violation of whistleblower protection laws, unjust enrichment, violation of public policy, and any Claims under ADEA, 29 U.S.C. § 626, as amended, the Older Workers Benefit Protection Act of 1990 (“OWBPA”), 29 U.S.C. § 626(f), Title VII of the Civil Rights Act of 1964 (“Title VII”), 42 U.S.C. § 2000e, et seq., the Americans with Disabilities Act (“ADA”), as amended by the ADA Amendments Act of 2008 (“ADAAA”), 29 U.S.C. § 12101, et seq., the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended, 29 U.S.C. §§ 1001, et seq., the Equal Pay Act (“EPA”), 29 U.S.C. § 206(d), the Family and Medical Leave Act (“FMLA”), 29 U.S.C. § 2601, et seq., the Genetic Information Nondiscrimination Act of 2008 (“XXXX”), the Minnesota Human Rights Act (“MHRA”), Minn. Stat. § 363A.01, et seq., Minnesota Statutes § 181, et seq., the Minnesota Whistleblower Act, Minn. Stat. § 181.931, et seq., Tennessee Human Rights Act and the Tennessee Disability Act, and any and all other Tennessee statutes, regulations, and ordinances related to fair employment practices or employment more generally, the False Claims Act, 31 U.S.C. § 3729, et seq., or any other state human rights or fair employment practices act, and any other federal, state, local or foreign statute, law, rule, regulation, ordinance or order. This includes, but is not limited to, Claims for violation of any civil rights laws based on protected class status and all other Claims for unlawful employment practices, and all other common law or statutory Claims. The Executive is not releasing and Claims shall not include any rights or Claims the Executive has (1) pursuant to the Separation Pay Agreement between the Executive and the Company, any equity award granted to the Executive by Xxxxxx Medical Group N.V. or the Indemnification Agreement between the Company or its affiliates and the Executive; (2) to be indemnified and advanced expenses in accordance with applicable law, or the Company’s and its affiliates’ corporate documents or to be covered under any applicable directors’ and officers’ liability insurance policies; (3) with respect to any rights which have accrued or become vested as of the date of this Release, including any rights to any outstanding equity awards; and (4) with respect to any Claims which arise after the Effective Date of this Release. This Release complies with the Older Workers Benefit Protection Act of 1990, as amended from time to time.

  • Xxxxxxxx, President ACKNOWLEDGED AND ACCEPTED -------------------------

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!